Published in final edited form as:

Oral Oncol. 2019 May ; 92: 26–32. doi:10.1016/j.oraloncology.2019.03.010.

How patients with an intact immune system develop head and neck cancer

Sarah Greene¹, Priya Patel¹, and Clint T. Allen¹

¹Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, National Institutes of health, Bethesda, MD

Abstract

Although the adaptive immune system can detect and eliminate malignant cells, patients with intact and fully functional immune systems develop head and neck cancer. How is this paradox explained? Manuscripts published in the English language from 1975 to 2018 were reviewed using search inputs related to tumor cell antigenicity and immunogenicity, immunodominance, cancer immunoediting and genomic alterations present within carcinomas. Early in tumor development, T cell responses to immunodominant antigens may lead to the elimination of cancer cells expressing these antigens and a tumor composed to tumor cells expressing only immunorecessive antigens. Conversely, other tumor cells may acquire genomic or epigenetic alterations that result in an antigen processing or presentation defect or other inability to be detected or killed by T cells. Such T cell insensitive tumor cells may also be selected for in a progressing tumor. Tumors harboring subpopulations of cells that cannot be eliminated by T cells may require non-T cell-based treatments, such as NK cell immunotherapies. Recognition of such tumor cell populations within a heterogeneous cancer may inform the selection of treatment for HNSCC in the future.

Keywords

Immunodominance; immune escape; antigenicity; immunogenicity; immunotherapy

Introduction

Genomic rearrangement of T cell receptor (TCR) genes produces an estimated 10^{13} different T cell clonotypes giving the adaptive immune system the capacity to respond to a large

Corresponding author: Clint T. Allen, MD, National Institutes of health, 10 Center Drive, Room 7N240C, Bethesda, MD, 20892, Phone: 301-827-5620; clint.allen@nih.gov.

Authorship

Conception and design or analysis and interpretation of data: SG, PP, CTA Drafting of the manuscript or revising it for important intellectual content: SG, PP, CTA Final approval of the version to be published: SG, PP, CTA

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Meetings presented

None

Conflict of Interest Statement

The authors have no conflicts of interest to disclose

number of unique antigens¹. These antigens, presented to T cells via major histocompatibility complex (MHC) molecules, can be derived from foreign pathogens or, in the case of cancer, from altered endogenous proteins. When altered or mutated endogenous proteins are processed and presented on MHC with subsequent recognition by T cells, these antigens are termed neoantigens. Head and neck squamous cell carcinomas (HNSCCs) typically harbor many genomic alterations and thus, HNSCCs are predicted to harbor many neoantigens^{2–4}. So how do cancers with many genomic alterations and neoantigens escape T cell recognition and elimination? One evasive mechanism employed by malignant cells is the expression of chemokines and cytokines that generate an immunosuppressive tumor microenvironment blocking the function of effector immune cells^{5–7}. However, development of an immunosuppressive tumor microenvironment may primarily be a mechanism of immune suppression in later-stage tumors that have accumulated a mass of tumor cells that produce chemokines sufficient to mediate chemotaxis of immunosuppressive cells⁵.

Early in tumor development, it is likely that variable *antigenicity* of tumor cells drives the formation of a tumor composed of tumor cells that are able to escape immunity⁸. The genomic instability of malignant cells results in a high degree of cancer cell heterogeneity⁹. Some tumor cells harbor strong (immunodominant) T cell antigens that are likely eliminated by the host's immune system early in tumor development¹⁰. This process, termed immunoediting, leads to the development of clinically relevant tumors that only harbor weaker (immunorecessive) antigens¹¹. Complicating this further, antigen-specific T cells tend to develop against immunodominant and not immunorecessive antigens, even when the immunodominant antigen has been removed from the tumor via immunoediting^{12–14}. Therefore, some tumors may be susceptible to immune detection and elimination if T cell responses against immunorecessive antigens develop, either naturally or after immunotherapy designed to activate T cell immunity.

Aside from differences in tumor cell antigenicity driving immune escape, differences in *immunogenicity* (or how well the tumor cell is recognized by T cells) may also be playing a role. Through genomic instability and selection pressure in the face of anti-tumor immunity, tumor cells that harbor genomic or epigenetic alterations that interfere with antigen processing and presentation, interferon responses or susceptibility to T cell killing may also be selected by the immune system^{15–18}. Translationally, this is more ominous and means that some cancers may simply be resistant to immunotherapy designed to activate T cell immunity, even if they harbor T cell antigens. Here, we review the underlying genomic alterations present within tumor cells that lead to resistance to T cell recognition and killing. Recognizing and fully elucidating these intrinsic mechanisms of resistance is required to begin to devise means of reversing these processes to enhance the efficacy of therapies relying on cytotoxic T cell responses.

How should antigen-specific T cell immunity develop?

Analysis of how tumor cells evade T cell detection and elimination requires an understanding of the normal biology. The process of T cell detection of infected or cancerous cells begins when clonally expanded antigen-specific T cells recognize antigen presented on the surface of target cells via MHC class I (MHC I). To maximize chances that

they see the antigen for which they are specific, activated T cells express interferon gamma (IFN γ) that in turn potently induces MHC class I expression on tumor cells through the IFN receptor/JAK/STAT signaling pathway¹⁹. Integrins and cell adhesion molecules strengthen the immunological synapse and “hold” T cells to target cells for a period of time to allow effector function and killing. Antigen:MHC complex binding to the antigen specific T cell receptor (TCR) triggers rapid release of preformed granules containing perforin and granzymes. Upon cell entry, granzymes mediate the early (first 8–16 hours) cytotoxic effects of T cells by acting as potent proteases and activating caspase-independent apoptosis^{20,21}. Secondary mechanisms of T cell killing that occur after granule exocytosis include expression of tumor necrosis factor (TNF)-superfamily ligands such as TNF α , Fas ligand and TRAIL. The ligands bind different TNF family receptors to activate extrinsic apoptosis pathways. One or more genomic alterations or epigenetic expression defects in any of these biologic processes could act as a mechanism of resistance to T cell recognition and killing.

This review will categorically explore intrinsic mechanisms of resistance to T cell recognition and killing that have been identified in head and neck cancers:

- 1) altered antigen processing and presentation
- 2) absent or defective IFN γ receptor expression or downstream signaling
- 3) defective formation of the immunologic synapse
- 4) neutralization of granzyme released from T cells
- 5) resistance to death receptor-induced extrinsic apoptosis
- 6) caspase mutations
- 7) tumor cell intrinsic cell cycle alterations in response to cytotoxic insults

Discussion

1) Alterations in antigen processing and presentation

For CTLs to recognize an antigen on MHC I, the cell must first generate peptide to serve as antigen. Figure 1 demonstrates critical steps in this process and common genomic alterations that disrupt antigen processing and presentation. Broadly, antigen processing and presentation requires successful cleavage of proteins to appropriate size, loading of the antigen onto the MHC I molecule and trafficking of the complex to the cell membrane. Defects in this process have been documented as a common cellular feature allowing for tumor evasion of CTL recognition and subsequent killing²². Antigens are most commonly peptides of 8–10 amino acids generated via ubiquitination and degradation by the multi-catalytic proteasome complex²³. Critical subunits of the multi-catalytic proteasome complex are IFN γ inducible²⁴ and loss of response to IFN γ may downregulate this process¹⁵.

Next, antigens are assembled with MHC I and β 2-microglobulin (B2M) in the endoplasmic reticulum. The MHC I peptide loading complex (PLC) is comprised of MHC I, the peptide transporter (TAP), the bridging factor tapasin, endoplasmic reticulum aminopeptidase and chaperones calreticulin, calnexin and ERp57^{25,26}. Loss or down regulation of TAP1 results in a global decrease in MHC I cell surface expression^{17,24,27}. Indeed, alterations in TAP1

expression occur in HNSCC at a rate of about 34%²⁸ with downregulation of TAP1 and tapasin occurring in both primary and metastatic lesions²⁹. Beyond the processing and loading machinery, issues may arise within the MHC I:B2M complex²⁷. Two copies of the B2M gene are present in each cell and only one copy is needed for MHC I antigen presentation³⁰; thus, loss of both functional B2M genes is required for loss of MHC I antigen presentation. Loss of both genes for this support protein renders tumor cells completed unresponsive to IFN γ stimulation of MHC I expression and unable to present antigens^{31,32}.

Similarly, the absence of structurally sound MHC Class I molecules may arise due to total or partial loss of one copy of chromosome 6, which encodes for MHC I heavy chains or loss of MHC allospecificity³³. Transcription of MHC I may be suppressed due to hypermethylation of DNA CpG islands, specifically of HLA-A, B and C promoter regions³⁴, and histone hypoacetylation³³. Transcription can be restored by DNA demethylating agents (5-azacytidine and decitabine) and histone deacetylases²². Thus, mutations or downregulation of either B2M or MHC I allows tumor cells to evade CTL recognition and elimination¹⁸. Clinically, loss of heterozygosity on chromosome 6p21, has been documented in HNSCC at a frequency of 36%²⁴ and MHC class I downregulation is associated with clinical reduction in disease free interval and overall survival²⁸. Finally, 80% of HNSCC are EGFR positive and EGFR-induced MHC I downregulation may contribute to resistance to T cell killing³⁵.

2) Absent or defective IFN γ receptor expression or downstream signaling

Cytotoxic T cells express interferon- γ which induces upregulation of MHC I expression in tumor cells³⁶. Binding of IFN γ to IFN γ receptor 1 and receptor 2 induces heterodimerization of the two components. Next, JAK2 phosphorylates the receptor allowing for binding of STAT1 proteins. STAT1 is phosphorylated, forms a homodimer and traffics to the nucleus²⁵. Once in the nucleus, STAT1 interacts with interferon regulatory factor 1 (IRF-1) to activate a wide variety of cellular responses including specific and nonspecific mechanisms of defense against viral infection and malignant transformation³⁷. Specifically, IFN γ is a major cytokine responsible for upregulation of MHC I, including induction of proteins required for MHC I:Antigen loading and processing such as TAP1, tapasin, calreticulin, calnexin and ERp57²⁵. Disruption of any of these components can result in defective IFN γ signaling and a decrease in or absence of MHC I presentation on the tumor cell surface¹⁵⁻¹⁷.

Both HPV-positive and -negative HNSCC are enriched for somatic mutations in the IFN γ receptor³⁸. Mutations in the JAK proteins have been widely documented in various cancer types, including melanoma³⁹, and can produce a variety of phenotypes. Homozygous loss of function mutation in JAK1 leads to resistance to IFN γ signaling in addition to loss of IFN α and IFN β response. In contrast, JAK2 mutations result in cells that are unresponsive to IFN γ only. Both mutations were documented in human melanoma lines and were correlated with initial tumor regression on immune checkpoint blockade with later disease progression⁴⁰. In tumor lines with functional JAK proteins, IFN γ signaling can be constitutively inhibited by suppressor of cytokine signaling-3 (SOCS3). SOCS3 inhibits JAK-STAT signaling through prolonged and extensive phosphorylation of STAT1 at the S727 site thus inhibiting

homodimerization translocation to the nucleus⁴¹. In contrast, Src homology 2 domain-containing phosphatase (SHP)-2 overexpression dephosphorylates pSTAH, also resulting in inhibited homodimerization and decreased expression of MHC I APM components^{42,43}. When taken together, phosphorylation of STAT1 must be tightly regulated for proper functioning of the IFN γ induced JAK-STAT pathway and dysregulation results in abrogation of pathway function. Finally, within the nucleus the STAT1 complex interacts with interferon regulatory factor 1 (IRF-1) to activate IFN inducible genes. Methylation of IRF-1 prevents binding by STAT1 and transactivation of IFN inducible genes³⁰. Encouragingly, demethylating agents have been shown to restore IFN γ induced MHC I expression⁴⁴.

3) Defective formation of immunologic synapse

Immune cells communicate directly with each other via cell-cell contacts also known as the immune synapse. Cytotoxic cells of the immune system also use this synapse during direct attacks on infected and tumor cells⁴⁵. Formation of the functional synapse requires the assembly of various structural components clustered around the central T-cell receptor, including the critical leukocyte function associated antigen-1 (LFA-1) which is activated when bound to intercellular adhesion molecule 1 (ICAM-1) on the antigen presenting cell⁴⁶. This interaction is especially critical in antitumor immune function (8666900) and can activate CD8+ T-cells in the absence of classical costimulatory molecules such as CD80 and CD86^{47,48}. It would then logically follow that down regulation of ICAM-1 would confer resistance to cytotoxic lymphocyte killing. Indeed, discovery of this key interaction was first described in melanoma cell lines and multiple groups have shown that ICAM-1 expression enhances *in vivo* lymphocyte adhesion in murine fibrosarcoma models^{49,50} and in breast, gastrointestinal and hematologic malignancies^{51–53}. However, establishing patterns of ICAM-1 expression in head and neck cancer has proved difficult with varying expression levels among patient samples and between cancer types^{54,55}. Patients with nasopharyngeal carcinoma and adenoid cystic carcinoma of the head and neck were demonstrated to have elevated soluble ICAM-1 in their sera as compared with normal controls^{54,56}. In the case of nasopharyngeal carcinoma, increased levels of soluble ICAM-1 were correlated with recurrence and poor prognosis⁵⁷ but in adenoid cystic carcinoma ICAM-1 downregulation was found to coexist with increased distant metastasis and poor prognosis⁵⁶. Thus, from a mechanistic stance down regulation of ICAM could confer resistance to CTL killing but *in vitro* evidence is lacking, and clinical correlates have yet to be fully elucidated.

4) Neutralization of granzyme release from T cells

After successful recognition and binding of the TCR to MHC I, T-cells can induce apoptosis of cancer cells via the granule exocytosis pathway, important in early onset target cell apoptosis^{20,21,58}. Activated lymphocytes secrete perforin, a membrane permeability protein, and granzymes, proteolytic enzymes that activate caspases⁵⁹, from cytotoxic granules toward the target cells. It is not fully understood whether release of perforin into the immunosynapse forms pores directly on the tumor plasma membrane to allow the entry of granzymes into the tumor cell or if the granules enter target tumors cells through receptor-mediated endocytosis followed by the subsequent perforin-dependent release of granzyme content from the endosome into tumor cytosol⁶⁰. It is known, however, that calcium-dependent polymerization of perforin leads to loss of plasma osmotic stability and leads to

the channel-like pore formation⁶¹. After pore formation, granzyme B is the main effector enzyme. Granzyme B causes target cell apoptosis directly through cleavage of BID, a member of the pro-apoptotic BCL-2 family^{62,63} resulting in cytochrome c release. Thus, granzyme B induced apoptosis acts in a caspase independent manner⁶⁴.

Tumor cells may be resistant to granzyme mediated apoptosis due to expression of the serine protease inhibitor (serpin) PI-9, or the murine counterpart SPI-6, which inactivates the effects of Granzyme B⁵⁹. Normally, PI-9 is expressed in immune privileged sites, such as in lymphoid tissue, on T lymphocytes, and on NK cells, possibly as a mechanism to inactivate immune cell self-destruction by Granzyme B^{65,66}. PI-6 is expressed in human melanoma, breast, cervical, and colon carcinomas and, notably, is not detectable in normal melanocytes, breast or cervical epithelium, or colon tissue⁶⁶. PI-9 expression on tumor cells is clinically associated with poorer outcomes in melanoma patients with metastatic disease⁶⁷.

5) Resistance to death receptor-induced extrinsic apoptosis

Late onset apoptosis mediated by T cells is largely induced through “death receptors” activated by tumor necrosis factor (TNF) receptor superfamily ligands such as Fas receptor (CD95/Apo-1) and death receptor (DR) 4 or 5, the receptors for tumor necrosis factor related apoptosis inducing ligand (TRAIL)^{21,68,69}. Specifically, T cells express surface FAS ligand (FasL or CD95L) which binds to Fas on cancer cells. Ligand binding to Fas leads to the recruitment of Fas-associated death domain (FADD) and procaspase-8 to form the death inducing signaling complex (DISC), which in turn recruits and cleaves procaspases to form active caspases resulting in cell apoptosis^{21,70}.

Fas is expressed in normal squamous epithelia, including gingival and basal cell layers. Malignant cells of head and neck cancer have variable expression of both Fas and FasL⁷⁰. In tobacco related intraoral carcinoma, for example, tumor cells downregulate Fas receptor and upregulate FasL, which confers not only resistance to CTL killing but provides a mechanism of tumor induced killing of anti-tumor immune cells that also express the Fas receptor. FasL expression is high in poorly differentiated oral squamous cell carcinoma and negatively correlated with the degree of apoptosis in these tumors⁷⁰.

The main mechanisms of tumor-intrinsic resistance to Fas-mediated apoptosis are overexpression of c-FLIP and expression of decoy receptors. c-FLIP, or cellular FLICE (FADD-like IL-1 β -converting enzyme)-inhibitory protein, is a relatively proximal anti-apoptotic protein that interacts with the Fas induced apoptosis pathway⁷¹. c-FLIP resembles procaspase-8 but lacks the catalytic site required for downstream death-inducing signaling complex formation and completion of apoptosis. An increased ratio of c-FLIP to caspase-8 expression is associated with increased resistance to Fas-mediated apoptosis⁷². Clinically, c-FLIP overexpression associated with higher clinical stage and lymph node metastases specifically in HNSCC⁷³. Cells can be re-sensitized to Fas mediated apoptosis by decreasing or silencing c-FLIP providing a possible therapeutic target. Silencing of c-FLIP utilizing the small molecule inhibitor MLN4924 has been pre-clinically studied in HNSCC⁷⁴ and melanoma^{72,75}, and clinical trials across a variety of cancer types are in progress. In oral squamous cell carcinoma, the PI3/AKT signaling cascade can enhance Fas-mediated

apoptosis through downregulation of cFLIP⁷⁶; however therapeutic benefits of this interaction have yet to be explored.

Notably, c-FLIP overexpression does not inhibit granzyme B-mediated apoptosis⁷⁷, but *in vivo* c-FLIP overexpression does result in tumor immune escape, suggesting that evasion Fas-dependent apoptosis may be a more influential mechanism for *in vivo* tumor immune escape than Granzyme B-mediated apoptosis^{78,79}. In a mouse model of viral FLIP (v-FLIP), tumor immune escape only occurred in immune competent mice and the effect of v-FLIP was not seen in mice lacking B and T cells further supporting the hypothesis that FLIPs effects on Fas-mediated apoptosis is directly related to cytotoxic lymphocyte killing⁸⁰. Finally, the possibility exists that c-FLIP's overall impact on cancer severity is related to c-FLIP's activating effects on the NFκB, MAPK, and ERK pathways^{71,81,82} in addition to increased resistance to CTL killing; however, these effects require further study.

Decoy receptors are members of the TNF receptor family that morphologically mimic true death receptors but lack a functional death domain^{79,83}. As a result, they competitively bind to FasL, and prevent Fas death receptor-induced apoptosis. Soluble Fas (sCD95) and decoy receptor 3 (DcR3) are two decoy receptors that prevent FasL binding^{83,84}. sCD95 is expressed in many cancer types, including melanoma⁸⁵ and is specifically associated with a worse prognosis in melanoma⁸⁶. DcR3 expression and function has been described in several cancer types⁸⁷. Tumor necrosis factor related apoptosis inducing ligand (TRAIL) is another member of the TNF superfamily expressed by cytotoxic lymphocytes that can initiate apoptosis by binding to its associated death receptors DR4 and DR5⁶⁹. These receptors induce apoptosis via the same mechanisms as the Fas mediated pathway; however, TRAIL mediated signaling can also induce cleavage of the proapoptotic BH3 protein Bid creating the active, truncated Bid (tBid), which in turn interacts with Bax and Bak at the mitochondrial membrane to release apoptotic factors, including cytochrome c^{69,88}.

HNSCC cells demonstrate resistance to TRAIL-death receptor mediated apoptosis via a variety of mechanisms. Beginning at the receptor site, resistance may be conferred by polymorphisms in DR4 resulting in loss of receptor function due to dominant negative expression of the mutated protein. Down regulation of DR5 receptor expression via histone deacetylation also confers resistance to CTL mediated killing⁸⁹. Malignant cells may also express TRAIL receptors DcR-1 and DcR-2, decoy receptors that do not possess an intracellular death domain and cannot form signaling complexes to induce apoptosis. These receptors have been documented in several cancer types including HNSCC⁹⁰.

6) Caspase Mutations

Caspase 8 is involved death receptor mediated mechanisms of cytotoxic T-lymphocyte killing and, to a lesser extent, granzyme B mediated apoptosis⁹¹. Caspase 8 mutations are associated with tumor resistance in many cancer types, including head and neck cancers^{92,93}. Caspase 8's critical role in the extrinsic apoptosis pathway likely means that mutated Caspase 8 results in a global decrease in extrinsic apoptosis pathway activation. In HNSCC, mutated procaspase-8 can be constitutively bound to FADD and can impair recruitment of DISC components. Finally, tumors bearing caspase 8 mutations are further associated with enhanced tumor migration, invasion, and growth⁹³.

7) Intrinsic cell cycle alterations in response to cytotoxic insults

Many tumors including HNSCC harbor mutations in proteins such as p53, p21 and Rb that affect the G1/S cell cycle checkpoint^{94,95}. As a result, cancer cells become more dependent upon the G2/M cell cycle checkpoint for cellular and DNA repair after exposure to cytotoxic or genotoxic insults. This gives cells time to repair injury before segregation of damaged DNA during mitosis. Cell cycle pause after insult has been a recognized phenomenon following chemotherapy and ionizing radiation for some time⁹⁶. More recent work has demonstrated that granzyme B and TNF- α similarly activate the G2/M cell cycle DNA damage checkpoint during early and late phases of T cell killing^{97–99}. This intrinsic mechanism of resisting damage and induction of apoptosis reduces tumor cell susceptibility to T cell killing. Reversal of G2/M cell cycle arrest via Wee1 kinase inhibition makes them more susceptible to *in vitro* and *in vivo* T-cell killing in multiple pre-clinical models including models of HNSCC^{99,100}.

Clinical repercussions of altered tumor cell immunogenicity—In tumors composed of cells that harbor intact IFN responses and T cell recognition pathways, lack of development of T cell responses to immunorecessive antigens may be overcome with immunotherapies such as immune checkpoint blockade¹⁰¹. However, the mechanisms of altered tumor cell immunogenicity described above suggest that a tumor cell could evade T cell recognition and destruction despite harboring one or more T cell antigens. Accordingly, recent genomic studies exploring predictors of response to immune checkpoint inhibitors have demonstrated tumors harboring alterations in IFN γ response genes and genes encoding for JAK1/2 and β 2M do not respond to treatment^{39,40,102,103}. If defects in immunogenicity are detected within a tumor, what other immunotherapy approaches could be effective? It likely depends upon which pathways are altered. If a tumor harbors defects in T cell antigen processing and presentation, defective immune synapse formation or response to IFN, these primarily alter TCR recognition of intracellular antigen presented via MHC I. Thus, immunotherapy that does not rely on TCR signaling such as NK cellular therapies (which are MHC and antigen independent) or chimeric antigen receptor (CAR) engineered T cellular therapies (which recognize a cell surface epitope similar to an antibody) may be effective. Conversely, if tumors harbor defects in responses to granzymes or TNFR superfamily ligands (FasL, TRAIL) or caspase mutations, then any form of immunotherapy is likely to be ineffective since both T and NK cellular therapeutics ultimately use the same mechanisms to destroy a tumor cell. In these situations, standard anti-cancer approaches such as surgical resection or localized ionizing radiation may be the only rational approach. Ultimately, integration of genomic characterization of tumors with different T and NK cell-based immunotherapy approaches is needed to determine if identification of such alterations predicts responses. If they do, this would be a major advance toward the ability to personalize treatment approaches for patients with HNSCC.

Conclusions

Recent advances in cancer immunotherapies have indeed provided exciting therapeutic options for HNSCC patients; however, current FDA-approved therapies stimulate endogenous immunity being blocked by immune checkpoints only. This can certainly

benefit some patients. Yet, many tumors harbor cells with defects in antigen processing and presentation, responses to IFN, and direct susceptibility to T cell killing through granzymes and TNFR superfamily ligands. As a result, some tumors may harbor a population of cells that simply cannot be detected and/or destroyed by T cells. Only through complete genomic characterization of tumors and a thorough understanding of how immune cells detect and eliminate tumor cells can we hope to prospectively assign specific immunotherapy or standard anti-cancer therapy approaches to individual patients in a personalized fashion. As more immunotherapy tools are developed that are independent of T cells, such as NK cellular therapies, integration of genomic characterization into prospective trials to determine which tumor genomic alterations predict responses to which immunotherapy becomes critical. Such ability is a major goal of the immunotherapy research community in order to minimize treatment of cancer patients with treatment approaches that have little to no chance of patient benefit.

Acknowledgments

Grant support

This work was supported by the Intramural Research Program of the NIH, NIDCD, project number ZIA-DC000087.

References

1. Nikolich-Zugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. *Nat Rev Immunol*. 2004;4(2):123–132. [PubMed: 15040585]
2. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature*. 2013;499(7457):214–218. [PubMed: 23770567]
3. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. *Science*. 2015;348(6230):69–74. [PubMed: 25838375]
4. Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. *Science*. 2015;350(6257):207–211. [PubMed: 26359337]
5. Davis RJ, Van Waes C, Allen CT. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. *Oral Oncol*. 2016;58:59–70. [PubMed: 27215705]
6. Curry JM, Spradlio J, Cognetti D, et al. Tumor microenvironment in head and neck squamous cell carcinoma. *Semin Oncol*. 2014;41(2):217–234. [PubMed: 24787294]
7. Hadrup S, Donia M, Thor Straten P. Effector CD4 and CD8 T cells and their role in the tumor microenvironment. *Cancer Microenviron*. 2013;6(2):123–133. [PubMed: 23242673]
8. Greaves M. Evolutionary determinants of cancer. *Cancer Discov*. 2015;5(8):806–820. [PubMed: 26193902]
9. Mroz EA, Tward AD, Pickering CR, Myers JN, Ferris RL, Rocco JW. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. *Cancer*. 2013;119(16):3034–3042. [PubMed: 23696076]
10. Urban JL, Kripke ML, Schreiber H. Stepwise immunologic selection of antigenic variants during tumor growth. *J Immunol*. 1986;137(9):3036–3041. [PubMed: 3489784]
11. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. *Nat Rev Immunol*. 2006;6(11):836–848. [PubMed: 17063185]
12. Sandberg JK, Grufman P, Wolpert EZ, Franksson L, Chambers BJ, Karre K. Superdominance among immunodominant H-2Kb-restricted epitopes and reversal by dendritic cell-mediated antigen delivery. *J Immunol*. 1998;160(7):3163–3169. [PubMed: 9531271]

13. Van Waes C, Monach PA, Urban JL, Wortzel RD, Schreiber H. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. *Tissue Antigens*. 1996;47(5):399–407. [PubMed: 8795140]
14. Seung S, Urban JL, Schreiber H. A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. *J Exp Med*. 1993;178(3):933–940. [PubMed: 8394406]
15. Katlinski KV, Gui J, Katlinskaya YV, et al. Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. *Cancer Cell*. 2017;31(2):194–207. [PubMed: 28196594]
16. Albacker LA, Wu J, Smith P, et al. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. *PLoS One*. 2017;12(11):e0176181. [PubMed: 29121062]
17. Johnsen AK, Templeton DJ, Sy M, Harding CV. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. *J Immunol*. 1999;163(8):4224–4231. [PubMed: 10510359]
18. McGranahan N, Rosenthal R, Hiley CT, et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. *Cell*. 2017;171(6):1259–1271 e1211. [PubMed: 29107330]
19. Raval A, Puri N, Rath PC, Saxena RK. Cytokine regulation of expression of class I MHC antigens. *Exp Mol Med*. 1998;30(1):1–13. [PubMed: 9873816]
20. Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. *Cell*. 1994;76(6):977–987. [PubMed: 8137431]
21. Shresta S, Pham CT, Thomas DA, Graubert TA, Ley TJ. How do cytotoxic lymphocytes kill their targets? *Curr Opin Immunol*. 1998;10(5):581–587. [PubMed: 9794837]
22. Lampen MH, van Hall T. Strategies to counteract MHC-I defects in tumors. *Curr Opin Immunol*. 2011;23(2):293–298. [PubMed: 21295956]
23. Madden DR. The three-dimensional structure of peptide-MHC complexes. *Annu Rev Immunol*. 1995;13:587–622. [PubMed: 7612235]
24. Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. *Cancer Immunol Immunother*. 2008;57(11):1719–1726. [PubMed: 18408926]
25. Hansen TH, Bouvier M. MHC class I antigen presentation: learning from viral evasion strategies. *Nat Rev Immunol*. 2009;9(7):503–513. [PubMed: 19498380]
26. Kalu DN, Foster GV. Calcitonin. Its physiologic roles. *N Y State J Med*. 1976;76(2):230–233. [PubMed: 1061871]
27. Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. *Vaccine*. 2002;20 Suppl 4:A40–45. [PubMed: 12477427]
28. Chang CC, Campoli M, Ferrone S. Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. *Adv Cancer Res*. 2005;93:189–234. [PubMed: 15797448]
29. Bandoh N, Ogino T, Katayama A, et al. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. *Oncol Rep*. 2010;23(4):933–939. [PubMed: 20204276]
30. Seliger B, Ritz U, Abele R, et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. *Cancer Res*. 2001;61(24):8647–8650. [PubMed: 11751378]
31. D'Urso CM, Wang ZG, Cao Y, Tataka R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. *J Clin Invest*. 1991;87(1):284–292. [PubMed: 1898655]
32. Sucker A, Zhao F, Real B, et al. Genetic evolution of T-cell resistance in the course of melanoma progression. *Clin Cancer Res*. 2014;20(24):6593–6604. [PubMed: 25294904]
33. Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. *Oncogene*. 2008;27(45):5869–5885. [PubMed: 18836468]

34. Nie Y, Yang G, Song Y, et al. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. *Carcinogenesis*. 2001;22(10):1615–1623. [PubMed: 11577000]
35. Pollack BP, Sapkota B, Cartee TV. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. *Clin Cancer Res*. 2011;17(13):4400–4413. [PubMed: 21586626]
36. Tau GZ, Cowan SN, Weisburg J, Braunstein NS, Rothman PB. Regulation of IFN-gamma signaling is essential for the cytotoxic activity of CD8(+) T cells. *J Immunol*. 2001;167(10):5574–5582. [PubMed: 11698428]
37. Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. *Annu Rev Immunol*. 1997;15:563–591. [PubMed: 9143700]
38. Gillison ML, Akagi K, Xiao W, et al. Human papillomavirus and the landscape of secondary genetic alterations in oral cancers. *Genome Res*. 2019;29(1):1–17.
39. Shin DS, Zaretsky JM, Escuin-Ordinas H, et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. *Cancer Discov*. 2017;7(2):188–201. [PubMed: 27903500]
40. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. *N Engl J Med*. 2016;375(9):819–829. [PubMed: 27433843]
41. Kovarik A, Fojtova M, Boudny V, Adamkova L, Lauerova L, Kovarik J. Interferon-gamma, but not interferon-alpha, induces SOCS 3 expression in human melanoma cell lines. *Melanoma Res*. 2005;15(6):481–488. [PubMed: 16314732]
42. Leibowitz MS, Srivastava RM, Andrade Filho PA, et al. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. *Clin Cancer Res*. 2013;19(4):798–808. [PubMed: 23363816]
43. Agazie YM, Hayman MJ. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. *Mol Cell Biol*. 2003;23(21):7875–7886. [PubMed: 14560030]
44. Rodriguez T, Mendez R, Del Campo A, et al. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. *BMC Cancer*. 2007;7:34. [PubMed: 17319941]
45. Dieckmann NM, Frazer GL, Asano Y, Stinchcombe JC, Griffiths GM. The cytotoxic T lymphocyte immune synapse at a glance. *J Cell Sci*. 2016;129(15):2881–2886. [PubMed: 27505426]
46. Braakman E, Goedegebuure PS, Vreugdenhil RJ, Segal DM, Shaw S, Bolhuis RL. ICAM-melanoma cells are relatively resistant to CD3-mediated T-cell lysis. *Int J Cancer*. 1990;46(3):475–480. [PubMed: 1975566]
47. de Waal Malefyt R, Verma S, Bejarano MT, Ranes-Goldberg M, Hill M, Spits H. CD2/LFA-3 or LFA-1/ICAM-1 but not CD28/B7 interactions can augment cytotoxicity by virus-specific CD8+ cytotoxic T lymphocytes. *Eur J Immunol*. 1993;23(2):418–424. [PubMed: 7679643]
48. Jenkinson SR, Williams NA, Morgan DJ. The role of intercellular adhesion molecule-1/LFA-1 interactions in the generation of tumor-specific CD8+ T cell responses. *J Immunol*. 2005;174(6):3401–3407. [PubMed: 15749873]
49. Turner J, Rhee JG, Fabian DF, Lefor AT. Expression of ICAM-1 enhances in vivo lymphocyte adhesion in a murine fibrosarcoma. *J Surg Oncol*. 1997;66(1):39–44. [PubMed: 9290691]
50. Sartor WM, Kyprianou N, Fabian DF, Lefor AT. Enhanced expression of ICAM-1 in a murine fibrosarcoma reduces tumor growth rate. *J Surg Res*. 1995;59(1):66–74. [PubMed: 7630139]
51. Rosette C, Roth RB, Oeth P, et al. Role of ICAM1 in invasion of human breast cancer cells. *Carcinogenesis*. 2005;26(5):943–950. [PubMed: 15774488]
52. Mizoi T, Ohtani H, Suzuki Y, Shiiba K, Matsuno S, Nagura H. Intercellular adhesion molecule-1 expression by macrophages in human gastrointestinal carcinoma: possible roles as host immune/inflammatory reaction. *Pathol Int*. 1995;45(8):565–572. [PubMed: 7496501]
53. Terol MJ, Tormo M, Martinez-Climent JA, et al. Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome. *Ann Oncol*. 2003;14(3):467–474. [PubMed: 12598355]

54. Liu CM, Sheen TS, Ko JY, Shun CT. Circulating intercellular adhesion molecule 1 (ICAM-1), E-selectin and vascular cell adhesion molecule 1 (VCAM-1) in head and neck cancer. *Br J Cancer*. 1999;79(2):360–362. [PubMed: 9888481]
55. Akcay F, Taysi S, Uslu C, Dogru Y, Gumustekin K. Levels of soluble intercellular adhesion molecule-1 and total sialic acid in serum of patients with laryngeal cancer. *Jpn J Clin Oncol*. 2001;31(12):584–588. [PubMed: 11902488]
56. Shirai A, Furukawa M, Yoshizaki T. Expression of intercellular adhesion molecule (ICAM)-1 in adenoid cystic carcinoma of the head and neck. *Laryngoscope*. 2003;113(11):1955–1960. [PubMed: 14603055]
57. Yu Y, Dong W, Zhou X, Li S. The significance of serum soluble intercellular adhesion molecule 1 and transforming growth factor alpha in patients with nasopharyngeal carcinoma. *Arch Otolaryngol Head Neck Surg*. 2004;130(10):1205–1208. [PubMed: 15492170]
58. Kawaguchi Y, Kono K, Mizukami Y, Mimura K, Fujii H. Mechanisms of escape from trastuzumab-mediated ADCC in esophageal squamous cell carcinoma: relation to susceptibility to perforin-granzyme. *Anticancer Res*. 2009;29(6):2137–2146. [PubMed: 19528474]
59. Medema JP, de Jong J, Peltenburg LT, et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. *Proc Natl Acad Sci U S A*. 2001;98(20):11515–11520. [PubMed: 11562487]
60. Spicer BA, Conroy PJ, Law RHP, Voskoboinik I, Whisstock JC. Perforin-A key (shaped) weapon in the immunological arsenal. *Semin Cell Dev Biol*. 2017;72:117–123. [PubMed: 28757431]
61. Motyka B, Korbitt G, Pinkoski MJ, et al. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. *Cell*. 2000;103(3):491–500. [PubMed: 11081635]
62. Heibein JA, Goping IS, Barry M, et al. Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax. *J Exp Med*. 2000;192(10):1391–1402. [PubMed: 11085742]
63. Pinkoski MJ, Waterhouse NJ, Heibein JA, et al. Granzyme B-mediated apoptosis proceeds predominantly through a Bcl-2-inhibitable mitochondrial pathway. *J Biol Chem*. 2001;276(15):12060–12067. [PubMed: 11278459]
64. Barry M, Heibein JA, Pinkoski MJ, et al. Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. *Mol Cell Biol*. 2000;20(11):3781–3794. [PubMed: 10805722]
65. Sun J, Bird CH, Sutton V, et al. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. *J Biol Chem*. 1996;271(44):27802–27809. [PubMed: 8910377]
66. Bladergroen BA, Strik MC, Bovenschen N, et al. The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. *J Immunol*. 2001;166(5):3218–3225. [PubMed: 11207275]
67. van Houdt IS, Oudejans JJ, van den Eertwegh AJ, et al. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. *Clin Cancer Res*. 2005;11(17):6400–6407. [PubMed: 16144945]
68. Krammer PH. CD95's deadly mission in the immune system. *Nature*. 2000;407(6805):789–795. [PubMed: 11048730]
69. Yuan X, Gajan A, Chu Q, Xiong H, Wu K, Wu GS. Developing TRAIL/TRAIL death receptor-based cancer therapies. *Cancer Metastasis Rev*. 2018.
70. Loro LL, Vintermyr OK, Johannessen AC, Liavaag PG, Jonsson R. Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma. *J Oral Pathol Med*. 1999;28(2):82–87. [PubMed: 9950255]
71. Safa AR. Roles of c-FLIP in Apoptosis, Necroptosis, and Autophagy. *J Carcinog Mutagen*. 2013;Suppl 6.
72. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. *J Immunol*. 1998;161(6):2833–2840. [PubMed: 9743343]

73. Li X, Pan X, Zhang H, et al. Overexpression of cFLIP in head and neck squamous cell carcinoma and its clinicopathologic correlations. *J Cancer Res Clin Oncol*. 2008;134(5):609–615. [PubMed: 17922291]
74. Zhao L, Yue P, Lonial S, Khuri FR, Sun SY. The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells. *Mol Cancer Ther*. 2011;10(12):2415–2425. [PubMed: 21914854]
75. Irmeler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. *Nature*. 1997;388(6638):190–195. [PubMed: 9217161]
76. Kondo G, Iwase M, Watanabe H, et al. Enhancement of susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells by phosphatidylinositol 3-kinase inhibitor. *Oral Oncol*. 2006;42(7):745–752. [PubMed: 16527514]
77. Kataoka T, Schroter M, Hahne M, et al. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. *J Immunol*. 1998;161(8):3936–3942. [PubMed: 9780161]
78. Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. *J Exp Med*. 1999;190(7):1033–1038. [PubMed: 10510093]
79. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. *Nat Rev Cancer*. 2002;2(4):277–288. [PubMed: 12001989]
80. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. *J Exp Med*. 1999;190(7):1025–1032. [PubMed: 10510092]
81. Kataoka T, Budd RC, Holler N, et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. *Curr Biol*. 2000;10(11):640–648. [PubMed: 10837247]
82. Hu WH, Johnson H, Shu HB. Activation of NF-kappaB by FADD, Casper, and caspase-8. *J Biol Chem*. 2000;275(15):10838–10844. [PubMed: 10753878]
83. Ashkenazi A Targeting death and decoy receptors of the tumour-necrosis factor superfamily. *Nat Rev Cancer*. 2002;2(6):420–430. [PubMed: 12189384]
84. Topfer K, Kempe S, Muller N, et al. Tumor evasion from T cell surveillance. *J Biomed Biotechnol*. 2011;2011:918471. [PubMed: 22190859]
85. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. *Cancer Res*. 1996;56(17):3870–3874. [PubMed: 8752148]
86. Ugurel S, Rapp L, Tilgen W, Reinhold U. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. *Clin Cancer Res*. 2001;7(5):1282–1286. [PubMed: 11350895]
87. Roth W, Isenmann S, Nakamura M, et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. *Cancer Res*. 2001;61(6):2759–2765. [PubMed: 11289159]
88. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. *J Pathol*. 2003;199(3):275–288. [PubMed: 12579529]
89. Jazirehi AR, Kurdistan SK, Economou JS. Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway. *J Immunol*. 2014;192(8):3981–3989. [PubMed: 24639349]
90. Nguyen PT, Nguyen D, Chea C, Miyauchi M, Fujii M, Takata T. Interaction between N-cadherin and decoy receptor-2 regulates apoptosis in head and neck cancer. *Oncotarget*. 2018;9(59):31516–31530. [PubMed: 30140387]
91. Medema JP, Toes RE, Scaffidi C, et al. Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T lymphocyte-induced apoptosis. *Eur J Immunol*. 1997;27(12):3492–3498. [PubMed: 9464839]
92. Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. *J Exp Med*. 1997;186(5):785–793. [PubMed: 9271594]

93. Li C, Egloff AM, Sen M, Grandis JR, Johnson DE. Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. *Mol Oncol*. 2014;8(7):1220–1230. [PubMed: 24816188]
94. Shaw PH. The role of p53 in cell cycle regulation. *Pathol Res Pract*. 1996;192(7):669–675. [PubMed: 8880867]
95. Cancer Genome Atlas N Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature*. 2015;517(7536):576–582. [PubMed: 25631445]
96. Fu S, Wang Y, Keyomarsi K, Meric-Bernstein F. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. *Expert Opin Investig Drugs*. 2018;27(9):741–751.
97. Chen G, Shi L, Litchfield DW, Greenberg AH. Rescue from granzyme B-induced apoptosis by Wee1 kinase. *J Exp Med*. 1995;181(6):2295–2300. [PubMed: 7539047]
98. Darzynkiewicz Z, Williamson B, Carswell EA, Old LJ. Cell cycle-specific effects of tumor necrosis factor. *Cancer Res*. 1984;44(1):83–90. [PubMed: 6690064]
99. Sun L, Moore E, Berman R, et al. WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy. *Oncoimmunology*. 2018;7(10):e1488359. [PubMed: 30288354]
100. Friedman J, Morisada M, Sun L, et al. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies. *J Immunother Cancer*. 2018;6(1):59. [PubMed: 29925431]
101. Memarnejadian A, Meilleur CE, Shaler CR, et al. PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8(+) T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination. *J Immunol*. 2017;199(9):3348–3359. [PubMed: 28939757]
102. Ayers M, Lunceford J, Nebozhyn M, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. *J Clin Invest*. 2017;127(8):2930–2940. [PubMed: 28650338]
103. Gao J, Shi LZ, Zhao H, et al. Loss of IFN-gamma Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. *Cell*. 2016;167(2):397–404 e399. [PubMed: 27667683]

Highlights

- Tumor cells presenting immunodominant antigens may be eliminated by immunity
- Tumor mutations may make other tumor cells invisible to T cells
- Both of these processes lead to selection of tumor cells that escape immunity
- Recognition of these tumor subpopulations may guide treatment in the future

Figure 1 –. Frequent genomic alterations present within head and neck squamous cell carcinomas that lead to escape from T cell immunity.

Illustration of common genomic alterations identified within head and neck squamous cell carcinomas that result in defective antigen processing and presentation. IFN- γ , interferon- γ ; IFNG-R, interferon- γ receptor; JAK, janus kinase; STAT, signal transducer and activator of transcription; IRF1, interferon regulatory factor-1; ISRE, interferon-sensitive response element; TAP, transporter 1, ATP binding cassette subfamily B member; MHC-I, major histocompatibility complex-1; β_2m , β -2-microglobulin; TCR, T-cell receptor